Morgan Stanley
CCCC icon

Morgan Stanley’s C4 Therapeutics CCCC Stock Holding History

Morgan Stanley’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.4M Sell
8,867,338
-205,062
-2% -$701K ﹤0.01% 2424
2026
Q1 		$23.9M Buy
9,072,400
+90,738
+1% +$214K ﹤0.01% 2788
2025
Q4 		$17.2M Buy
8,981,662
+4,009,630
+81% +$9.5M ﹤0.01% 3074
2025
Q3 		$11M Buy
4,972,032
+217,844
+5% +$523K ﹤0.01% 3460
2025
Q2 		$6.8M Buy
4,754,188
+708,859
+18% +$1.03M ﹤0.01% 3800
2025
Q1 		$6.47M Buy
4,045,329
+205,860
+5% +$614K ﹤0.01% 3706
2024
Q4 		$13.8M Buy
3,839,469
+1,513,335
+65% +$7.52M ﹤0.01% 3097
2024
Q3 		$13.3M Buy
2,326,134
+1,188,196
+104% +$7.15M ﹤0.01% 3203
2024
Q2 		$5.26M Buy
1,137,938
+623,755
+121% +$3.72M ﹤0.01% 3831
2024
Q1 		$4.2M Buy
514,183
+308,842
+150% +$2.39M ﹤0.01% 4043
2023
Q4 		$1.16M Sell
205,341
-107,736
-34% -$246K ﹤0.01% 4839
2023
Q3 		$582K Buy
313,077
+72,038
+30% +$220K ﹤0.01% 5102
2023
Q2 		$663K Sell
241,039
-53,099
-18% -$171K ﹤0.01% 5072
2023
Q1 		$924K Sell
294,138
-85,061
-22% -$501K ﹤0.01% 4907
2022
Q4 		$2.24M Buy
379,199
+34,812
+10% +$289K ﹤0.01% 4380
2022
Q3 		$3.02M Sell
344,387
-111,069
-24% -$1.15M ﹤0.01% 4109
2022
Q2 		$3.43M Sell
455,456
-202,116
-31% -$1.78M ﹤0.01% 4098
2022
Q1 		$16M Sell
657,572
-260,898
-28% -$6.34M ﹤0.01% 2366
2021
Q4 		$29.6M Buy
918,470
+628,374
+217% +$24.8M ﹤0.01% 1754
2021
Q3 		$13M Buy
290,096
+13,908
+5% +$596K ﹤0.01% 2587
2021
Q2 		$10.5M Buy
276,188
+254,993
+1,203% +$9.13M ﹤0.01% 2923
2021
Q1 		$784K Buy
21,195
+12,087
+133% +$481K ﹤0.01% 4879
2020
Q4 		$302K Buy
+9,108
New +$264K ﹤0.01% 5368

Other funds holding CCCC

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Morgan Stanley's CCCC Position: Q2 2026 in Review

Morgan Stanley reduced its C4 Therapeutics (CCCC) stake by 2.3% in Q2 2026, selling an estimated $701K and leaving 8,867,338 shares worth $41.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2424.

Morgan Stanley first reported a position in CCCC in Q4 2020 and has held it in 23 quarters since. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Morgan Stanley held 8,867,338 shares of C4 Therapeutics worth $41.4M as of Q2 2026.
  • Morgan Stanley sold 205,062 C4 Therapeutics shares in Q2 2026, an estimated $701K.
  • C4 Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #2424 holding.
  • Morgan Stanley first reported a position in C4 Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.